FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245278300> ?p ?o ?g. }

• W4245278300 endingPage "557" @default.
• W4245278300 startingPage "551" @default.
• W4245278300 abstract "In Brief Objective To determine whether serum estradiol and dydrogesterone concentrations are associated with the occurrence of breakthrough bleeding. Methods In a prospective, double-blind study, 194 postmenopausal women were allocated randomly to receive one of four doses of dydrogesterone (2.5 mg, 5 mg, 10 mg, 15 mg) continuously combined with 2 mg of micronized 17β-estradiol. All medication was taken orally for a total of 168 days. Vaginal bleeding was recorded on a daily basis. Serum estradiol (E2) and dihydrodydrogesterone (the main metabolite of dydrogesterone) trough levels were measured at day 85 and at the end of the study (day 168). Bleeding pattern analysis was done according to the reference period method. Results One hundred fifty-two of 177 women who completed the study supplied valid data on drug compliance, smoking habits, bleeding episodes, and serum hormone concentrations, which were used to assess the impact of serum E2 and dihydrodydrogesterone concentrations on the occurrence of breakthrough bleeding. Logistic regression analysis identified only the serum E2 concentration as having an independent, statistically significant effect (P = .003) on the occurrence of breakthrough bleeding; no such effect was associated with dihydrodydrogesterone levels (P = .118). The relative risk for the occurrence of breakthrough bleeding was 2.7 (95% confidence interval [CI] 1.454, 5.609) for serum E2 concentrations greater than 40 pg/mL. Conclusion The occurrence of breakthrough bleeding during continuous combined hormone replacement therapy with estradiol and dydrogesterone in postmenopausal women was related to serum estradiol levels and not to dydrogesterone levels. Further studies are needed to test the hypothesis that estrogen is a major factor in the incidence of bleeding during postmenopausal hormone replacement therapy. Breakthrough bleeding during continuous combined hormone replacement therapy with estradiol and dydrogesterone is related to serum estradiol levels, not to serum dydrogesterone levels." @default.
• W4245278300 created "2022-05-12" @default.
• W4245278300 creator A5026878274 @default.
• W4245278300 creator A5042093124 @default.
• W4245278300 creator A5051560890 @default.
• W4245278300 creator A5091492238 @default.
• W4245278300 date "1999-04-01" @default.
• W4245278300 modified "2023-09-25" @default.
• W4245278300 title "Relationship of Estradiol Levels to Breakthrough Bleeding During Continuous Combined Hormone Replacement Therapy" @default.
• W4245278300 cites W1549372639 @default.
• W4245278300 cites W1976880298 @default.
• W4245278300 cites W1996659292 @default.
• W4245278300 cites W2024536285 @default.
• W4245278300 cites W2024877841 @default.
• W4245278300 cites W2028831724 @default.
• W4245278300 cites W2039235094 @default.
• W4245278300 cites W2050108803 @default.
• W4245278300 cites W2055054480 @default.
• W4245278300 cites W2063031738 @default.
• W4245278300 cites W2064114517 @default.
• W4245278300 cites W2068731114 @default.
• W4245278300 cites W2079450135 @default.
• W4245278300 cites W2083676646 @default.
• W4245278300 cites W2135922883 @default.
• W4245278300 cites W2136358824 @default.
• W4245278300 cites W2162008912 @default.
• W4245278300 cites W2272037979 @default.
• W4245278300 cites W4254016327 @default.
• W4245278300 doi "https://doi.org/10.1097/00006250-199904000-00016" @default.
• W4245278300 hasPublicationYear "1999" @default.
• W4245278300 type Work @default.
• W4245278300 citedByCount "0" @default.
• W4245278300 crossrefType "journal-article" @default.
• W4245278300 hasAuthorship W4245278300A5026878274 @default.
• W4245278300 hasAuthorship W4245278300A5042093124 @default.
• W4245278300 hasAuthorship W4245278300A5051560890 @default.
• W4245278300 hasAuthorship W4245278300A5091492238 @default.
• W4245278300 hasConcept C126322002 @default.
• W4245278300 hasConcept C151956035 @default.
• W4245278300 hasConcept C2776045411 @default.
• W4245278300 hasConcept C2777164284 @default.
• W4245278300 hasConcept C2779279991 @default.
• W4245278300 hasConcept C2780159708 @default.
• W4245278300 hasConcept C44249647 @default.
• W4245278300 hasConcept C71315377 @default.
• W4245278300 hasConcept C71924100 @default.
• W4245278300 hasConcept C90924648 @default.
• W4245278300 hasConceptScore W4245278300C126322002 @default.
• W4245278300 hasConceptScore W4245278300C151956035 @default.
• W4245278300 hasConceptScore W4245278300C2776045411 @default.
• W4245278300 hasConceptScore W4245278300C2777164284 @default.
• W4245278300 hasConceptScore W4245278300C2779279991 @default.
• W4245278300 hasConceptScore W4245278300C2780159708 @default.
• W4245278300 hasConceptScore W4245278300C44249647 @default.
• W4245278300 hasConceptScore W4245278300C71315377 @default.
• W4245278300 hasConceptScore W4245278300C71924100 @default.
• W4245278300 hasConceptScore W4245278300C90924648 @default.
• W4245278300 hasIssue "4" @default.
• W4245278300 hasLocation W42452783001 @default.
• W4245278300 hasOpenAccess W4245278300 @default.
• W4245278300 hasPrimaryLocation W42452783001 @default.
• W4245278300 hasRelatedWork W1975556624 @default.
• W4245278300 hasRelatedWork W1977859733 @default.
• W4245278300 hasRelatedWork W1983099204 @default.
• W4245278300 hasRelatedWork W1999116046 @default.
• W4245278300 hasRelatedWork W2009238780 @default.
• W4245278300 hasRelatedWork W2039175448 @default.
• W4245278300 hasRelatedWork W2412926515 @default.
• W4245278300 hasRelatedWork W2766929056 @default.
• W4245278300 hasRelatedWork W3152945096 @default.
• W4245278300 hasRelatedWork W3184619506 @default.
• W4245278300 hasVolume "93" @default.
• W4245278300 isParatext "false" @default.
• W4245278300 isRetracted "false" @default.
• W4245278300 workType "article" @default.